In MPN, these publications constantly report the predominance of mutations affecting epigenetic regulators, including ASXL1 (22–to 36%, 4–11% and 3–12% in PMF, ET and PV), TET2 (18–22%, 11–16% and 15–22%), and DNMT3A (5–9%, 6% and 2–4%) [45,46,47]. This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.